Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Dawn, Zhu"'
Autor:
Fang-Tsao Hong, Hongyan Li, Derek E. Piper, Leszek Poppe, Philip Wong, Todd Hager, Essa Hu, Jason Long, Jennifer Aral, Narender R. Gavva, Cen Xu, Les P. Miranda, Carl Davis, Dawn Zhu, Sonya G. Lehto, Licheng Shi, Kristin L. Andrews
Publikováno v:
Journal of Medicinal Chemistry. 64:3427-3438
Inhibition of the pituitary adenylate cyclase 1 receptor (PAC1R) is a novel mechanism that could be used for abortive treatment of acute migraine. Our research began with comparative analysis of known PAC1R ligand scaffolds, PACAP38 and Maxadilan, wh
Autor:
Licheng Shi, Bryan D. Moyer, Margarida Martins-Oliveira, Hong Sun, Sonya G. Lehto, Peter J. Goadsby, Simon Akerman, Jan Hoffmann, Dawn Zhu, Weera Supronsinchai, Ruoyuan Yin, Cen Xu, Silke Miller, Judy Wang, Hantao Liu
Publikováno v:
Hoffmann, J R, Miller, S, Martins-Oliveira, M, Akerman, S, Supronsinchai, W, Sun, H, Shi, L, Wang, J, Zhu, D, Lehto, S, Liu, H, Yin, R, Moyer, B D, Xu, C & Goadsby, P 2020, ' PAC1 receptor blockade reduces central nociceptive activity: new approach for primary headache? ', Pain, vol. 161, no. 7, pp. 1670-1681 . https://doi.org/10.1097/j.pain.0000000000001858
Pain
Pain
PAC1 receptor blockade using a monoclonal antibody inhibits nociceptive neuronal activity in the trigeminocervical complex.
Pituitary adenylate cyclase activating polypeptide-38 (PACAP38) may play an important role in primary headaches. Preclini
Pituitary adenylate cyclase activating polypeptide-38 (PACAP38) may play an important role in primary headaches. Preclini
Autor:
Kristin Taborn, Joseph Ligutti, Josie H. Lee, Thomas Kornecook, Dong Liu, Dawn Zhu, Stephen Altmann, Ruoyuan Yin, Xuhai Be, Robert T. Fremeau, Jinti Wang, John Roberts, David J. Matson, Danielle Johnson, Violeta Yu, Christopher P Ilch, Bryan D. Moyer, Jason A. Luther, Virginia Berry, Matthew Weiss, Danny Ortuno, Michael Jarosh, Sonya G. Lehto
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 362:146-160
Potent and selective antagonists of the voltage-gated sodium channel NaV1.7 represent a promising avenue for the development of new chronic pain therapies. We generated a small molecule atropisomer quinolone sulfonamide antagonist AMG8379 and a less
Autor:
Jessica Able, Benjamin C. Milgram, Loren Berry, Melanie Cooke, Liyue Huang, John Butler, Hongbing Huang, Violeta Yu, Kristin Taborn, John D. Roberts, Steven Altmann, Margaret Y. Chu-Moyer, John Yeoman, Jean Wang, Roman Shimanovich, Russell Graceffa, Matthew Weiss, Thomas Kornecook, Christopher P Ilch, Bryan D. Moyer, Christiane Boezio, Isaac E. Marx, Brian A. Sparling, Emily A. Peterson, Gwen Rescourio, Charles Kreiman, Elma Feric Bojic, Karina R. Vaida, Angel Guzman-Perez, Dawn Zhu, Hua Gao, Laurie B. Schenkel, Michael Jarosh, Hanh Nho Nguyen, Joseph Ligutti, Alessandro Boezio, Hakan Gunaydin, Daniel S. La, Thomas Dineen, Robert T. Fremeau, Robert S. Foti, Min-Hwa Jasmine Lin, Erin F. DiMauro, John Stellwagen
Publikováno v:
Journal of Medicinal Chemistry. 60:5990-6017
Because of its strong genetic validation, NaV1.7 has attracted significant interest as a target for the treatment of pain. We have previously reported on a number of structurally distinct bicyclic heteroarylsulfonamides as NaV1.7 inhibitors that demo
Autor:
Russell F, Graceffa, Alessandro A, Boezio, Jessica, Able, Steven, Altmann, Loren M, Berry, Christiane, Boezio, John R, Butler, Margaret, Chu-Moyer, Melanie, Cooke, Erin F, DiMauro, Thomas A, Dineen, Elma, Feric Bojic, Robert S, Foti, Robert T, Fremeau, Angel, Guzman-Perez, Hua, Gao, Hakan, Gunaydin, Hongbing, Huang, Liyue, Huang, Christopher, Ilch, Michael, Jarosh, Thomas, Kornecook, Charles R, Kreiman, Daniel S, La, Joseph, Ligutti, Benjamin C, Milgram, Min-Hwa Jasmine, Lin, Isaac E, Marx, Hanh N, Nguyen, Emily A, Peterson, Gwen, Rescourio, John, Roberts, Laurie, Schenkel, Roman, Shimanovich, Brian A, Sparling, John, Stellwagen, Kristin, Taborn, Karina R, Vaida, Jean, Wang, John, Yeoman, Violeta, Yu, Dawn, Zhu, Bryan D, Moyer, Matthew M, Weiss
Publikováno v:
Journal of medicinal chemistry. 60(14)
Because of its strong genetic validation, Na
Autor:
Eszter Pakai, Andrej A. Romanovsky, A. Gomtsyan, Narender R. Gavva, Dawn Zhu, Joshua J. Corrigan, R. M. Reilly, H. A. McDonald, Sonya G. Lehto, P. R. Kym, Erika Pintér, András Garami
Publikováno v:
Acta Physiologica. 223:e13038
Aim Thermoregulatory side effects hinder the development of transient receptor potential vanilloid-1 (TRPV1) antagonists as new painkillers. While many antagonists cause hyperthermia, a well-studied effect, some cause hypothermia. The mechanisms of t
Autor:
Mark H. Norman, Lana Klionsky, Maosheng Zhang, Jue Wang, Ella Magal, Sekhar Surapaneni, Rami Tamir, Judy Wang, John Rubino, Hong Deng, Jean-Claude Louis, Dawn Zhu, Doo Lee, Barton H. Manning, Tingrong Wang, Weiya Wang, April Le, Nuria A. Tamayo, Rongzhen Kuang, Narender R. Gavva, Sonya G. Lehto, Brad Youngblood
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 326:218-229
Antagonists of the vanilloid receptor TRPV1 (transient receptor potential vanilloid type 1) have been reported to produce antihyperalgesic effects in animal models of pain. These antagonists, however, also caused concomitant hyperthermia in rodents,
Autor:
Tie J. Zhang, James W. Davis, Di Bian, Jean-Claude Louis, Dawn Zhu, Anthony W. Bannon, Kenneth D. Wild
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 322:282-287
A considerable body of evidence implicates endogenous nerve growth factor (NGF) in conditions in which pain is a prominent feature, including neuropathic pain. However, previous studies of NGF antagonism in animal models of neuropathic pain have exam
Autor:
David C. Immke, Brian Smith, Jianhua Zhang, Hong Sun, Sonya G. Lehto, Licheng Shi, Kenneth D. Wild, Cen Xu, Dawn Zhu
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 356(1)
Therapeutic agents that block the calcitonin gene-related peptide (CGRP) signaling pathway are a highly anticipated and promising new drug class for migraine therapy, especially after reports that small-molecule CGRP-receptor antagonists are efficaci
Autor:
Narender R. Gavva, James J. S. Treanor, Todd W. Vanderah, Yusheng Qu, Jean Claude Louis, Tie J. Zhang, Frank Porreca, Kenneth D. Wild, Elizabeth M. Doherty, Rami Tamir, David C. Immke, Anthony W. Bannon, Mark H. Norman, Lana Klionsky, Judy Wang, Dawn Zhu
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 313:474-484
The vanilloid receptor 1 (VR1 or TRPV1) is a membrane-bound, nonselective cation channel expressed by peripheral sensory neurons. TRPV1 antagonists produce antihyperalgesic effects in animal models of inflammatory and neuropathic pain. Here, we descr